Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety in Healthy Adults Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

I.V. Selonabant in Healthy Adult Subjects

NCT07211607
View directory record Official record
Conditions
Healthy Volunteers
Interventions
selonabant, placebo
Drug
Lead sponsor
Anebulo Pharmaceuticals
Industry
Eligibility
18 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DMID 23-0015; Lassa Fever CVD 1000

NCT06546709
View directory record Official record
Conditions
Lassa Fever
Interventions
LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU
Biological · Other
Lead sponsor
Wilbur Chen, MD, MS
Other
Eligibility
18 Years to 50 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 30, 2026, 8:03 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers Results available

The Safety and Efficacy Study of RiaGev in Healthy Adults

NCT04483011
View directory record Official record
Conditions
Metabolic Syndrome, Premature Aging
Interventions
RiaGev
Dietary Supplement
Lead sponsor
Bioenergy Life Science, Inc.
Industry
Eligibility
36 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of PNT001 in Healthy Adults

NCT04096287
View directory record Official record
Conditions
Healthy
Interventions
PNT001, Placebo
Biological · Drug
Lead sponsor
Pinteon Therapeutics, Inc
Industry
Eligibility
21 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Rogers, Arkansas • San Diego, California • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers

NCT04984525
View directory record Official record
Conditions
Healthy
Interventions
SYNB1934, SYNB1618
Drug
Lead sponsor
Synlogic
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647

NCT05105048
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
North Hollywood, California • San Diego, California • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 30, 2026, 8:03 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Study to Evaluate a Human Monoclonal Antibody (MAb) 10E8VLS Administered Alone or Concurrently With MAb VRC07-523LS Via Subcutaneous Injection in Healthy Adults

NCT03565315
View directory record Official record
Conditions
Healthy Adult Immune Response
Interventions
VRC-HIVMAB095-00-AB (10E8VLS), VRC-HIVMAB075-00-AB (VRC07-523LS)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine

NCT00664417
View directory record Official record
Conditions
Influenza, Orthomyxoviridae Infections
Interventions
Monovalent subvirion H5N1 influenza vaccine, Physiological saline
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 40 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
6
States / cities
San Diego, California • South Miami, Florida • Springfield, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2012 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial to Evaluate Safety and Immunogenicity of Trivalent Seasonal Influenza Virus-Like Particle (VLP) Vaccine (Recombinant)

NCT00903552
View directory record Official record
Conditions
Seasonal Influenza
Interventions
Influenza VLP Vaccine, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
18 Years to 49 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Pembroke Pines, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05338515
View directory record Official record
Conditions
Healthy
Interventions
Selpercatinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects

NCT01705938
View directory record Official record
Conditions
Exposure
Interventions
SP-333
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults

NCT00515385
View directory record Official record
Conditions
West Nile Virus
Interventions
MGAWN1, Placebo
Drug · Other
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of MK-1167 in Healthy Adults (MK-1167-010)

NCT07266818
View directory record Official record
Conditions
Healthy
Interventions
MK-1167, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population

NCT04801420
View directory record Official record
Conditions
Lyme Borreliosis
Interventions
VLA15, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
5 Years to 65 Years
Enrollment
625 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
19
States / cities
Bridgeport, Connecticut • Stamford, Connecticut • Waterbury, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Single Doses of IV Aerucin in Healthy Adults

NCT02486770
View directory record Official record
Conditions
Healthy
Interventions
Aerucin 2.0mg/kg, Aerucin 8.0mg/kg, Aerucin 20.0 mg/kg
Biological
Lead sponsor
Aridis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 30, 2015 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional

Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection

NCT00709605
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVADV014-00-VP
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 30, 2026, 8:03 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety and Immunogenicity of a Higher Dose of the Study Vaccine, VIR-1388, in HCMV-seropositive Adult Participants Without HIV

NCT07801456
View directory record Official record
Conditions
Cytomegalovirus (CMV), HIV (Human Immunodeficiency Virus)
Interventions
VIR-1388, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Birmingham, Alabama • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

NCT05872958
View directory record Official record
Conditions
COVID-19
Interventions
AZD3152, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of DZD2269 in Healthy Adult Participants

NCT04932005
View directory record Official record
Conditions
Healthy Volunteers
Interventions
DZD2269, placebo
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 30, 2026, 8:03 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function

NCT07315360
View directory record Official record
Conditions
Renal Impairment, Healthy
Interventions
PF-07328948
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
4
States / cities
Lake Forest, California • Orlando, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Prime-Boost Vaccine Regimen in HIV-Uninfected Vaccine-Naive Adults

NCT00820846
View directory record Official record
Conditions
HIV Infections
Interventions
pGA2/JS7 DNA vaccine, Placebo, MVA/HIV62 vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
299 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

NCT02773979
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Chloroquine, PfSPZ (NF54) Challenge, Placebo
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 30, 2026, 8:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

NCT05229562
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 30, 2026, 8:03 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults

NCT06620003
View directory record Official record
Conditions
Marburg Virus Disease
Interventions
cAd3-Marburg Vaccine, Placebo
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
7
States / cities
Huntsville, Alabama • Phoenix, Arizona • Melbourne, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 8:03 PM EDT